These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35628345)

  • 1. Development of a Novel Anti-CD44 Monoclonal Antibody for Multiple Applications against Esophageal Squamous Cell Carcinomas.
    Goto N; Suzuki H; Tanaka T; Asano T; Kaneko MK; Kato Y
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Anti-CD44 Variant 3 Monoclonal Antibody C
    Suzuki H; Kitamura K; Goto N; Ishikawa K; Ouchida T; Tanaka T; Kaneko MK; Kato Y
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Novel Anti-CD44 Variant 6 Monoclonal Antibody C
    Ejima R; Suzuki H; Tanaka T; Asano T; Kaneko MK; Kato Y
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Novel Anti-CD44 Variant 4 Monoclonal Antibody C
    Suzuki H; Tanaka T; Goto N; Kaneko MK; Kato Y
    Curr Issues Mol Biol; 2023 Feb; 45(3):1875-1888. PubMed ID: 36975491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Novel Anti-CD44 Variant 7/8 Monoclonal Antibody, C
    Suzuki H; Ozawa K; Tanaka T; Kaneko MK; Kato Y
    Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of a Novel Anti-CD44 Variant 10 Monoclonal Antibody C
    Ishikawa K; Suzuki H; Kaneko MK; Kato Y
    Curr Issues Mol Biol; 2023 Jun; 45(7):5248-5262. PubMed ID: 37504249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Novel Anti-CD44 Variant 5 Monoclonal Antibody C
    Kudo Y; Suzuki H; Tanaka T; Kaneko MK; Kato Y
    Antibodies (Basel); 2023 Apr; 12(2):. PubMed ID: 37218897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas.
    Ishikawa K; Suzuki H; Ohishi T; Li G; Tanaka T; Kawada M; Ohkoshi A; Kaneko MK; Katori Y; Kato Y
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Anti-CD44 Variant 9 Monoclonal Antibody C
    Tawara M; Suzuki H; Goto N; Tanaka T; Kaneko MK; Kato Y
    Curr Issues Mol Biol; 2023 Apr; 45(4):3658-3673. PubMed ID: 37185762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody C
    Suzuki H; Goto N; Tanaka T; Ouchida T; Kaneko MK; Kato Y
    Antibodies (Basel); 2023 Jul; 12(3):. PubMed ID: 37489367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of high CD44 expression in oral cancers using the novel monoclonal antibody, C
    Yamada S; Itai S; Nakamura T; Yanaka M; Kaneko MK; Kato Y
    Biochem Biophys Rep; 2018 Jul; 14():64-68. PubMed ID: 29872736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epitope Mapping of the Anti-CD44 Monoclonal Antibody (C
    Asano T; Kaneko MK; Takei J; Tateyama N; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Aug; 40(4):156-161. PubMed ID: 34283655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activities of anti‑CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer.
    Ishikawa K; Suzuki H; Ohishi T; Nakamura T; Yanaka M; Li G; Tanaka T; Ohkoshi A; Kawada M; Kaneko MK; Katori Y; Kato Y
    Oncol Rep; 2024 Nov; 52(5):. PubMed ID: 39219278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitope Mapping of the Anti-CD44 Monoclonal Antibody (C
    Takei J; Asano T; Suzuki H; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Oct; 40(5):219-226. PubMed ID: 34678095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitope Mapping of an Anti-CD44v4 Monoclonal Antibody (C
    Suzuki H; Tawara M; Hirayama A; Goto N; Tanaka T; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2024 Jun; 43(3):85-89. PubMed ID: 38507669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications.
    Li G; Suzuki H; Asano T; Tanaka T; Suzuki H; Kaneko MK; Kato Y
    Antibodies (Basel); 2022 Jun; 11(2):. PubMed ID: 35735360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an Anti-EphB4 Monoclonal Antibody for Multiple Applications Against Breast Cancers.
    Nanamiya R; Suzuki H; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2023 Oct; 42(5):166-177. PubMed ID: 37824755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A defucosylated anti‑CD44 monoclonal antibody 5‑mG2a‑f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
    Takei J; Kaneko MK; Ohishi T; Hosono H; Nakamura T; Yanaka M; Sano M; Asano T; Sayama Y; Kawada M; Harada H; Kato Y
    Oncol Rep; 2020 Nov; 44(5):1949-1960. PubMed ID: 33000243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of a Novel Anti-Human CCR6 Monoclonal Antibody C
    Tanaka T; Kitamura K; Suzuki H; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2023 Aug; 42(4):117-124. PubMed ID: 37428612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crosstalk between MMP-13, CD44, and TWIST1 and its role in regulation of EMT in patients with esophageal squamous cell carcinoma.
    Mahmoudian RA; Gharaie ML; Abbaszadegan MR; Alasti A; Forghanifard MM; Mansouri A; Gholamin M
    Mol Cell Biochem; 2021 Jun; 476(6):2465-2478. PubMed ID: 33604811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.